PHIO Stock Catalyst: Phio Pharmaceuticals Concludes Safety Review for PH-762 in Phase 1b Trial

Feb 9, 2026 · 7:26pm ET

The Safety Monitoring Committee completed its planned safety review.

Max move

+74.2%

High of day $1.58

Sparker timei

7:26pm ET

PHIO · Feb 9, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced that the Safety Monitoring Committee has concluded its planned safety review for all patients treated with the INTASYL compound PH-762 in the company's Phase 1b Trial.

The review assessed the safety of PH-762, a key component in Phio's ongoing clinical trial. The company did not report any safety concerns following the committee's evaluation.

As of the latest data, Phio Pharmaceuticals has a free float of 5,677,000 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time PHIO sparks.

Download Sniper App →

Catch the next PHIO-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →